Healthcare / Biotech
FDA Approves Regeneron's Livsayis, a Four-Times-a-Year Treatment for Myasthenia Gravis
The quarterly shot is the first siRNA therapy in the disease, Regeneron says, pairing a modest symptom gain with a far lighter dosing burden.
The FDA approved Regeneron's Livsayis on Wednesday for generalized myasthenia gravis, dosed under the skin just four times a year.
The U.S. Food and Drug Administration approved Livsayis (cemdisiran) on Wednesday, November 18, 2026. It covers adults with anti-acetylcholine receptor (AChR) antibody-positive disease, the predominant form of gMG, Regeneron says.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is based in Tarrytown, New York.
Regeneron says Livsayis is the first and only siRNA therapy approved in gMG, and the only approved gMG treatment given under the skin four times a year.
The approval is Regeneron's first for an siRNA therapy and its first approved medicine in neurology.
A therapy that silences a complement protein
Livsayis is a small interfering RNA, or siRNA - a therapy that silences a specific gene's message. It degrades the messenger RNA encoding complement component factor 5, known as C5.
That lowers circulating C5 protein and limits terminal complement activation. In AChR-positive gMG, antibodies activate complement and disrupt communication between nerves and muscles.
Generalized myasthenia gravis is a rare, chronic autoimmune disease causing extreme fatigue and difficulty with facial expression, speech, swallowing, mobility and breathing.
Severe flare-ups, called myasthenic crises, can impair breathing enough to require hospitalization. Regeneron estimates about 85,000 people in the United States have myasthenia gravis.
What the NIMBLE trial showed
The approval rests on NIMBLE, an ongoing Phase 3 trial Regeneron calls the largest global, interventional gMG trial to date. It is randomized, double-blind and placebo-controlled in anti-AChR antibody-positive patients.
Patients could keep taking background immunosuppressants at their investigator's discretion.
The trial tested four regimens, including Livsayis alone every three months and a combination arm. The approval covers Livsayis itself; the results below are for that regimen.
The primary endpoint was change in MG-ADL score from baseline to week 24. MG-ADL is an eight-question scale, scored 0 to 24, where higher means greater severity.
Regeneron reported a least-squares mean improvement of 4.5 points on Livsayis, against 2.2 points on placebo. The placebo-adjusted improvement was 2.3 points, with p=0.0005.
Responders - patients improving at least three points - were 76.6% on Livsayis against 44.1% on placebo. Regeneron reported p<0.001 for that comparison.
The key secondary measure, QMG, is a 13-item clinician assessment scored 0 to 39. Improvement was 4.2 points on Livsayis against 1.5 points on placebo, a placebo-adjusted 2.8 points.
Regeneron reported p=0.0015 for QMG. QMG responders, improving at least five points, were 48.4% against 19.0%.
Regeneron says benefit appeared as early as two weeks - a clinically meaningful 2.5 MG-ADL points - sustained through 24 weeks with no indication of waning efficacy.
The absolute gain over placebo was modest: 2.3 points on a 24-point scale. The practical edge is the schedule: four subcutaneous doses a year.
A boxed warning and a restricted program
The prescribing information carries a Boxed Warning for serious meningococcal infections, plus warnings for other serious infections, consistent with other medicines that reduce C5 activity.
Livsayis is available only through the restricted Livsayis REMS program, a safety program controlling distribution. Patients must complete meningococcal vaccination at least two weeks before the first dose, or receive antibiotics if treatment must start sooner.
Patients with a serious meningococcal infection at treatment start must not receive the drug. Whether Livsayis is safe and effective in children is not known.
The most common adverse reactions, at 5% or more and more frequent than placebo, were injection site reactions, viral infections and urinary tract infections.
Dr. Tuan Vu, a NIMBLE global principal investigator at USF Morsani, said Livsayis “delivered rapid, deep disease control – maintained through the end of dosing intervals.”
The path beyond the United States
Regeneron is solely responsible for developing, manufacturing and selling Livsayis. It holds those rights under a worldwide licensing agreement with Alnylam.
No royalty or other economic terms were disclosed for that agreement. A European Union submission is under review, with a decision expected in the second half of 2027.
Submissions are planned in additional markets, including Japan, and the myRARE program offers benefits verification and financial-support information.
What remains unknown
What remains unknown starts with price: Regeneron announced none, so what patients and insurers will pay is not yet public.
How the drug performs beyond 24 weeks is also unknown: NIMBLE is ongoing and longer-term results have not been reported.
How Livsayis compares with existing C5-targeting medicines is unknown. The release reports no antibody-arm results, so no head-to-head comparison is available.
The tests that come next
The first test is commercial: whether a four-times-a-year schedule wins patients from more frequent regimens will show in early uptake.
The second test is European. A decision on the EU submission is expected in the second half of 2027.
The third test is durability: longer NIMBLE follow-up will show whether control holds past 24 weeks.
Sources & evidence
Source checked1 source · 6 figures
Figure receipts
Sources
Sources used for this piece.
As of Wednesday, Nov. 18, 2026.

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

